Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
March 20, 2019 08:00 ET
|
Fibrocell Science Inc.
- Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) - - Company to...
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
February 06, 2019 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Present at Phacilitate Leaders World 2019
January 16, 2019 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
December 11, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
November 13, 2018 08:00 ET
|
Fibrocell Science Inc.
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST – - Announces patient enrollment completed in Phase 2 of Phase 1/2 clinical trial for FCX-007 for recessive dystrophic...
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights
November 08, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007
October 25, 2018 08:00 ET
|
Fibrocell Science Inc.
Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019 EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc....
Fibrocell to Present at Upcoming Industry and Investor Conferences
September 26, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
September 25, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
September 05, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...